Sign in
CLSD Stock Price, Chart, Stats & News
Clearside Biomedical, Inc.
Save
Clearside Biomedical, Inc. (CLSD) does not currently pay a dividend.
2.15M
Market cap
–
Current P/E
–
Forward P/E
CLSD chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 85.55% |
Operating margin | -689.76% |
Pretax margin | -759.42% |
Net margin | -780.90% |
Effective tax rate | -2.83% |
ROA | -223.31% |
ROE | 55.47% |
D/E | -0.01x |
Interest coverage ratio | -2.17x |
CLSD valuation
P/E | – |
P/S | 0.64x |
P/B | -0.04x |
P/CF | -0.10x |
P/FCF | -0.10x |
P/OCF | -0.10x |
PEG | -0.01x |
EV multiple | -0.59x |
About
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to pioneering novel drug delivery methods to the posterior segment of the eye via the suprachoroidal space. Its commercial product, XIPERE, is a triamcinolone acetonide suprachoroidal injectable suspension designed for treating uveitis macular edema. The company's development pipeline also features CLS-AX, an axitinib injectable suspension administered into the suprachoroidal space, which is currently undergoing Phase 1/2a clinical trials.
Similar securities
Based on sector and market capitalization
Report issue